DIOSynVax

News

An AI-powered universal vaccine tech developed by UK biotech DIOSynVax has shown preliminary efficacy in a world-first human trial.

News

Ibrance has become the first CDK4/6 inhibitor to be approved for a challenging subtype of breast cancer that is often resistant to current treatment.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.